{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:29:12Z","timestamp":1792218552421,"version":"4.4.0"},"reference-count":156,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006595","name":"Ministry of Research, Innovation and Digitization, CNCS UEFISCDI","doi-asserted-by":"publisher","award":["PN-III-P1-1.1-TE-2021-1236"],"award-info":[{"award-number":["PN-III-P1-1.1-TE-2021-1236"]}],"id":[{"id":"10.13039\/501100006595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>As the backbone of oncological treatments, systemic chemotherapy is still one of the main pawns in cancer care, alone or in combination with newer targeted agents. All chemotherapy agents can be associated with a type of adverse event called an infusion reaction, which can be characterized as unpredictable, non-dose related, and unexplained by the cytotoxic profile of the drug. For some of these events, a certain immunological mechanism can be identified by blood or skin testing. In this case, we can speak of true hypersensitivity reactions that occur as a response to an antigen\/allergen. The current work summarizes the main antineoplastic therapy agents and their susceptibility to induce hypersensitivity reactions and also includes a review of clinical presentation, diagnostic methods in hypersensitivity reactions, and perspectives to overcome these negative events in the treatment of patients suffering from various types of cancer.<\/jats:p>","DOI":"10.3390\/ijms24043886","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:09:21Z","timestamp":1676430561000},"page":"3886","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-1750","authenticated-orcid":false,"given":"Bianca","family":"Galateanu","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania"},{"name":"Department of Drug Control, Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Ioana","family":"Pu\u0219ca\u0219u","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Andreea","family":"Tircol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Gastroenterology), Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan Cosmin","family":"Tanase","sequence":"additional","affiliation":[{"name":"Institute of Oncology Prof. Dr. A. Trestioreanu Bucharest, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-9432","authenticated-orcid":false,"given":"Ariana","family":"Hudita","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania"},{"name":"Department of Drug Control, Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Negrei","sequence":"additional","affiliation":[{"name":"Departament of Toxicology, Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-2953","authenticated-orcid":false,"given":"George-Traian-Alexandru","family":"Burcea-Dragomiroiu","sequence":"additional","affiliation":[{"name":"Department of Drug Control, Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-0754","authenticated-orcid":false,"given":"Lucian","family":"Negreanu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Gastroenterology), Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana Adela","family":"Vacaroiu","sequence":"additional","affiliation":[{"name":"\u201cSf. Ioan\u201d Emergency Clinical Hospital, 042122 Bucharest, Romania"},{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octav","family":"Ginghin\u0103","sequence":"additional","affiliation":[{"name":"Department of Drug Control, Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Institute of Oncology Prof. Dr. A. Trestioreanu Bucharest, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The Pathophysiology of Anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","first-page":"620","article-title":"Mast Cell: A Multi-Functional Master Cell","volume":"6","author":"Dileepan","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_3","first-page":"iv100","article-title":"Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Blasco","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_4","first-page":"835","article-title":"The Complex Clinical Picture of Presumably Allergic Side Effects to Cytostatic Drugs: Symptoms, Pathomechanism, Reexposure, and Desensitization","volume":"94","author":"Pagani","year":"2010","journal-title":"Med. Clin."},{"key":"ref_5","unstructured":"Vaillant, A.A.J., Vashisht, R., and Zito, P.M. (2022). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/all.15113","article-title":"Hypersensitivity Reactions to Chemotherapy: An EAACI Position Paper","volume":"77","author":"Pagani","year":"2022","journal-title":"Allergy"},{"key":"ref_7","unstructured":"Castells, M.C., Matulonis, U.A., Horton, T.M., Adkinson, N.F., and Feldweg, A.M. (2015). Infusion Reactions to Systemic Chemotherapy, UpToDate."},{"key":"ref_8","unstructured":"Gilmans, G. (2006). The Pharmacological Basis of Therapeutics, McGraw-Hill."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rang, H.P., Dale, M.M., Ritter, J.M., Flower, R.J., and Henderson, G. (2011). Rang & Dale\u2019s Pharmacology, Elsevier Health Sciences.","DOI":"10.1016\/B978-0-7020-3471-8.00001-9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/SCT.2003.n.003","article-title":"Unique Aspects of Supportive Care Using Monoclonal Antibodies in Cancer Treatment","volume":"1","author":"Dillman","year":"2003","journal-title":"Support. Cancer Ther."},{"key":"ref_11","unstructured":"Koda-Kimble, M.A. (2012). Koda-Kimble and Young\u2019s Applied Therapeutics: The Clinical Use of Drugs, Lippincott Williams & Wilkins."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10555-013-9447-3","article-title":"Adverse Reactions to Targeted and Non-Targeted Chemotherapeutic Drugs with Emphasis on Hypersensitivity Responses and the Invasive Metastatic Switch","volume":"32","author":"Baldo","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-Targeted Cancer Therapies: Progress, Challenges and Future Directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_14","first-page":"676","article-title":"Mechanisms of Action of CD20 Antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.blre.2015.08.004","article-title":"Monoclonal Antibodies\u2014A New Era in the Treatment of Multiple Myeloma","volume":"30","author":"Jelinek","year":"2016","journal-title":"Blood Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and Safety of Rituximab (MabThera\u00ae)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2013.06.002","article-title":"Carboplatin-, Oxaliplatin-, and Cisplatin\u2013Specific IgE: Cross-Reactivity and Value in the Diagnosis of Carboplatin and Oxaliplatin Allergy","volume":"1","author":"Caiado","year":"2013","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2008.07.001","article-title":"Cutaneous Vasculitis in Breast Cancer Treated with Chemotherapy","volume":"129","author":"Wong","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_19","unstructured":"Chabner, B.A., and Longon, D.L. (2018). Cancer Chemotherapy, Immunotherapy and Biotherapy, Lippincott Williams & Wilkins."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity Reactions to Platinum Agents and Taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"207084","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met.-Based Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11882-015-0515-3","article-title":"Presentation and Diagnosis of Hypersensitivity to Platinum Drugs","volume":"15","author":"Caiado","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_23","first-page":"663","article-title":"Platinum Chemotherapy Hypersensitivity: Prevalence and Management","volume":"37","author":"Otani","year":"2017","journal-title":"Immunol. Allergy Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","article-title":"Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin Chemotherapy","volume":"19","author":"Zanotti","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Puxeddu, I., Petrelli, F., Guerrieri, M.E., Cosio, S., Del Corso, I., Rocchi, V., Manca, M.L., Migliorini, P., and Gadducci, A. (2021). The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study. Cancers, 13.","DOI":"10.3390\/cancers13215468"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1525-1438.2007.01063.x","article-title":"Analysis of the Pattern of Hypersensitivity Reactions in Patients Receiving Carboplatin Retreatment for Recurrent Ovarian Cancer","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","article-title":"Decreased Hypersensitivity Reactions with Carboplatin-Pegylated Liposomal Doxorubicin Compared to Carboplatin-Paclitaxel Combination: Analysis from the GCIG CALYPSO Relapsing Ovarian Cancer Trial","volume":"122","author":"Joly","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","article-title":"Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and Desensitization","volume":"2","author":"Wong","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","article-title":"Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin","volume":"8","author":"Silver","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000205263","article-title":"Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review","volume":"76","author":"Kim","year":"2009","journal-title":"Oncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdj042","article-title":"Hypersensitivity Reactions to Oxaliplatin: Experience in a Single Institute","volume":"17","author":"Siu","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00000421-200212000-00020","article-title":"Hypersensitivity Reaction to Cisplatin during Chemoradiation Therapy for Gynecologic Malignancy","volume":"25","author":"Koren","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaip.2019.12.032","article-title":"Allergy Evaluation of Hypersensitivity to Platinum Salts and Taxanes: A Six-Year Experience","volume":"8","author":"Pradelli","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jaip.2019.01.057","article-title":"Low Cross-Reactivity between Cisplatin and Other Platinum Salts","volume":"7","author":"Pasteur","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2006.10.047","article-title":"Does the Platinum-Free Interval Predict the Incidence or Severity of Hypersensitivity Reactions to Carboplatin? The Experience from Women and Infants\u2019 Hospital","volume":"105","author":"Schwartz","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0971-5851.133705","article-title":"Carboplatin Hypersensitivity in Relapsed Ovarian Carcinoma: A Therapeutic Challenge","volume":"35","author":"Pandey","year":"2014","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical Features of Hypersensitivity Reactions to Carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ygyno.2006.03.007","article-title":"Atypical Presentations of Carboplatin Hypersensitivity Reactions: Characterization and Management in Patients with Gynecologic Malignancies","volume":"103","author":"McAlpine","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk Stratification for Desensitization of Patients with Carboplatin Hypersensitivity: Clinical Presentation and Management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1186\/s12885-020-07582-x","article-title":"Long-Term Trends in Colorectal Cancer: Incidence, Localization, and Presentation","volume":"20","author":"Edna","year":"2020","journal-title":"BMC Cancer"},{"key":"ref_41","first-page":"372","article-title":"A Delayed Reaction to Oxaliplatin","volume":"22","author":"Masse","year":"2012","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000178163","article-title":"Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience","volume":"76","author":"Polyzos","year":"2009","journal-title":"Oncology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v18.i38.5427","article-title":"Oxaliplatin-Induced Severe Anaphylactic Reactions in Metastatic Colorectal Cancer: Case Series Analysis","volume":"18","author":"Wang","year":"2012","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00520-006-0107-9","article-title":"Severe Anaphylactic Reactions in Patients Receiving Oxaliplatin Therapy: A Rare but Potentially Fatal Complication","volume":"15","author":"Lee","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","article-title":"Allergic-Type Reactions to Oxaliplatin: Retrospective Analysis of 42 Patients","volume":"41","author":"Tournigand","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdg092","article-title":"Skin Testing and Hypersensitivity Reactions to Oxaliplatin","volume":"14","author":"Garufi","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_47","first-page":"949","article-title":"Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report","volume":"47","author":"Woo","year":"2015","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-3-12","article-title":"Hypersensitivity Reaction and Acute Immune-Mediated Thrombocytopenia from Oxaliplatin: Two Case Reports and a Review of the Literature","volume":"3","author":"Bautista","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jjco\/hyq162","article-title":"Sudden-Onset Pancytopenia with Intracranial Hemorrhage after Oxaliplatin Treatment: A Case Report and Literature Review","volume":"41","author":"Teng","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_50","first-page":"3115","article-title":"Fatal Thrombocytopenia after Oxaliplatin-Based Chemotherapy","volume":"28","author":"Shao","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaci.2014.09.045","article-title":"Hypersensitivity Reactions to Racemic Calcium Folinate (Leucovorin) during FOLFOX and FOLFIRI Chemotherapy Administrations","volume":"135","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/1078155210396577","article-title":"Leucovorin-Induced Hypersensitivity Reaction","volume":"18","author":"Damaske","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4236\/crcm.2021.1010037","article-title":"Anaphylaxis to Cisplatin after Carboplatin Hypersensitivity Reaction in Advanced Non-Small Cell Lung Cancer","volume":"10","author":"Dieu","year":"2021","journal-title":"Case Rep. Clin. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tjog.2020.05.013","article-title":"Nedaplatin Use in Patients with Hypersensitivity Reaction Episodes to Carboplatin","volume":"59","author":"Chikazawa","year":"2020","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12016-014-8416-0","article-title":"Re-Visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review","volume":"49","author":"Picard","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"(2011). A Fatal Anaphylactic Reaction to Paclitaxel Is Described, Which Was Preceded by a Possible Delayed Reaction to the Initial Infusion. Allergy Asthma Proc., 32, 79.","DOI":"10.2500\/aap.2011.32.3409"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000324454","article-title":"Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol","volume":"156","author":"Syrigou","year":"2011","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"19259","DOI":"10.5070\/D3198019259","article-title":"Taxane Associated Subacute Cutaneous Lupus Erythematosus","volume":"19","author":"Marchetti","year":"2013","journal-title":"Dermatol. Online J."},{"key":"ref_60","first-page":"1135","article-title":"Stevens-Johnson Syndrome Induced by Paclitaxel in a Patient with Squamous Cell Carcinoma of the Lung: A Case Report","volume":"24","author":"Hiraki","year":"2004","journal-title":"Anticancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/oxfordjournals.annonc.a058599","article-title":"Coping with Toxicities of Docetaxel (TaxotereTM)","volume":"4","author":"Schrijvers","year":"1993","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/oxfordjournals.annonc.a058883","article-title":"Phase II Trial of Docetaxel (Taxotere\u00ae) in Metastatic Colorectal Carcinoma","volume":"5","author":"Pazdur","year":"1994","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1186\/1756-0500-7-785","article-title":"Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Docetaxel Chemotherapy: A Case Report","volume":"7","author":"Wong","year":"2014","journal-title":"BMC Res. Notes"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hemonc.2013.08.005","article-title":"Docetaxel-Induced Hypersensitivity Pneumonitis Mimicking Lymphangitic Carcinomatosis in a Patient with Metastatic Adenocarcinoma of the Lung","volume":"6","author":"Taj","year":"2013","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.cad.0000131685.06390.b7","article-title":"Non-Allergic Nature of Docetaxel-Induced Acute Hypersensitivity Reactions","volume":"15","author":"Ardavanis","year":"2004","journal-title":"Anticancer Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejps.2011.09.016","article-title":"Complement Activation by Polyethoxylated Pharmaceutical Surfactants: Cremophor-EL, Tween-80 and Tween-20","volume":"45","author":"Rosivall","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.jaip.2020.08.005","article-title":"Controversies in Allergy: Chemotherapy Reactions, Desensitize, or Delabel?","volume":"8","author":"Hong","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0091-6749(99)70489-6","article-title":"Molecular Mechanisms of CD8+ T Cell\u2013Mediated Delayed Hypersensitivity: Implications for Allergies, Asthma, and Autoimmunity","volume":"103","author":"Kalish","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A Multicenter Phase II Study of XRP6258 Administered as a 1-h Iv Infusion Every 3 Weeks in Taxane-Resistant Metastatic Breast Cancer Patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_71","first-page":"440","article-title":"Cabazitaxel (Jevtana): A Novel Agent for Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Nightingale","year":"2012","journal-title":"Pharm. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomised Open-Label Trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/10600280211058385","article-title":"Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared with Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"56","author":"He","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"BCBCR-S5857","DOI":"10.4137\/BCBCR.S5857","article-title":"Safety and Efficacy of Nab-Paclitaxel in the Treatment of Patients with Breast Cancer","volume":"5","author":"Vishnu","year":"2011","journal-title":"Breast Cancer Basic Clin. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/jco.2005.23.16_suppl.2052","article-title":"Cross-Sensitivity between Paclitaxel and Docetaxel in a Women\u2019s Cancers Program","volume":"23","author":"Dizon","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.gynor.2013.05.003","article-title":"Successful Treatment with Nab-Paclitaxel after Hypersensitivity Reaction to Paclitaxel and Docetaxel","volume":"5","author":"Bolla","year":"2013","journal-title":"Gynecol. Oncol. Case Rep."},{"key":"ref_77","first-page":"329","article-title":"Hypersensitivity Reactions to Taxanes and Subsequent Treatment with Nab-Paclitaxel: Case Reports of 2 Women with Early-Stage Breast Cancer","volume":"11","author":"Carrera","year":"2021","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"ref_78","first-page":"329","article-title":"Nab-Paclitaxel after Docetaxel Hypersensitivity Reaction: Case Report and Literature Review","volume":"88","author":"Pellegrino","year":"2017","journal-title":"Acta Bio Medica Atenei Parm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/fon-2021-1288","article-title":"Hypersensitivity Reactions to Asparaginase Therapy in Acute Lymphoblastic Leukemia: Immunology and Clinical Consequences","volume":"18","author":"Burke","year":"2022","journal-title":"Future Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/bcp.14216","article-title":"A Comparison of Asparaginase Activity in Generic Formulations of E. Coli Derived L-asparaginase: In-vitro Study and Retrospective Analysis of Asparaginase Monitoring in Pediatric Patients with Leukemia","volume":"86","author":"Sankaran","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"182","DOI":"10.32641\/andespediatr.v92i2.2151","article-title":"Reacciones de Hipersensibilidad Asociadas al Uso de Asparaginasa En Ni\u00f1os Con Leucemia Linfobl\u00e1stica Aguda","volume":"92","author":"Ovalle","year":"2021","journal-title":"Andes Pediatr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF00262779","article-title":"Study of Histamine Release Induced by Acute Administration of Antitumor Agents in Dogs","volume":"21","author":"Eschalier","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4236\/ojbd.2020.102007","article-title":"Bleomycin Induced Drug Allergy Mimicking Herpes Skin Infection: A Case Report","volume":"10","author":"Lwin","year":"2020","journal-title":"Open J. Blood Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1001\/archinte.144.11.2267","article-title":"Fulminant and Fatal Angioedema Caused by Bleomycin Treatment","volume":"144","author":"Khansur","year":"1984","journal-title":"Arch. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.14740\/jmc3906","article-title":"Intraoperative Anaphylaxis Following Injection of a Bleomycin-Gelatin Solution for Sclerotherapy","volume":"13","author":"Roberts","year":"2022","journal-title":"J. Med. Cases"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fphar.2018.00578","article-title":"Bleomycin Aggravates Atopic Dermatitis via Lung Inflammation in 2, 4-Dinitrochlorobenzene-Induced NC\/Nga Mice","volume":"9","author":"Sung","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000353627","article-title":"Hypersensitivity to Etoposide in Case of Metastatic Gestational Choriocarcinoma","volume":"6","author":"Jeremic","year":"2013","journal-title":"Case Rep. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6600003","article-title":"Safe Administration of Etoposide Phosphate after Hypersensitivity Reaction to Intravenous Etoposide","volume":"86","author":"Siderov","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/ccr3.2732","article-title":"Severe Hypersensitivity Reaction to Etoposide Phosphate: A Case Report","volume":"8","author":"Cotteret","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1986.4.8.1262","article-title":"Hypersensitivity Reactions to Teniposide (VM-26): An Analysis","volume":"4","author":"King","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"ref_91","first-page":"808","article-title":"Doxorubicin-Induced Hypersensitivity Reactions","volume":"18","author":"Solimando","year":"1984","journal-title":"Drug Intell. Clin. Pharm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.1990.8.6.1093","article-title":"A Phase I Clinical Trial and Pharmacokinetic Evaluation of Liposome-Encapsulated Doxorubicin","volume":"8","author":"Rahman","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement Activation Following First Exposure to Pegylated Liposomal Doxorubicin (Doxil\u00ae): Possible Role in Hypersensitivity Reactions","volume":"14","author":"Szebeni","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_94","first-page":"376","article-title":"Anaphylaxis to Pegylated Liposomal Doxorubicin: A Case Report","volume":"63","author":"Sharma","year":"2014","journal-title":"West Indian Med. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/01.ftd.0000161930.34775.45","article-title":"Cyclophosphamide Hypersensitivity in a Leukemic Child","volume":"27","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0091-6749(96)70279-8","article-title":"Allergic Reactions to Cyclophosphamide: Delayed Clinical Expression Associated with Positive Immediate Skin Tests to Drug Metabolites in Five Patients","volume":"97","author":"Popescu","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF01714904","article-title":"Anaphylactoid Reaction with Bronchospasm Following Intravenous Cyclophosphamide Administration","volume":"62","author":"Salles","year":"1991","journal-title":"Ann. Hematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.anai.2022.04.023","article-title":"Mesna, an Unusual Agent Causing Hypersensitivity Reactions during Chemotherapy","volume":"129","author":"Wietstruck","year":"2022","journal-title":"Ann. Allergy. Asthma. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12948-022-00173-0","article-title":"Cutaneous Reaction to Ifosfamide plus Mesna Treated with Desensitization Challenge: A Case Report","volume":"20","author":"Farzanegan","year":"2022","journal-title":"Clin. Mol. Allergy"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jgf2.79","article-title":"Nonimmediate Allergic Reactions Induced by Mesna","volume":"18","author":"Shimogori","year":"2017","journal-title":"J. Gen. Fam. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/1078155215607090","article-title":"Cytarabine Syndrome despite Corticosteroid Premedication in an Adult Undergoing Induction Treatment for Acute Myelogenous Leukemia","volume":"22","author":"Jirasek","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5114\/ada.2018.75249","article-title":"A Desensitization Protocol for Delayed Allergy to Cytarabine: Analysis of Two Cases","volume":"35","author":"Albanesi","year":"2018","journal-title":"Adv. Dermatol. Allergol. Dermatol. Alergol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity Reactions to Therapeutic Monoclonal Antibodies: Phenotypes and Endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies","volume":"5","author":"Picard","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab Hypersensitivity: From Clinical Presentation to Management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-Related Reactions to Rituximab: Frequency, Mechanisms and Predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens\u2013Johnson Syndrome after Treatment with Rituximab","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2013-0286","article-title":"Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab","volume":"19","author":"Thompson","year":"2014","journal-title":"Oncologist"},{"key":"ref_110","unstructured":"LaCasce, A.S., Castells, M.C., Burstein, H.J., Meyerhardt, J.A., Adkinson, N.F., and Feldweg, A.M. (2019). Infusion-Related Reactions to Therapeutic Monoclonal Antibodies Used for Cancer Therapy, UpToDate."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ejhpharm-2016-001155","article-title":"Trastuzumab Infusion Reactions in Breast Cancer. Should We Routinely Observe after the First Dose?","volume":"25","author":"Price","year":"2018","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity Reactions to MAbs: 105 Desensitizations in 23 Patients, from Evaluation to Treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/j.annonc.2022.03.266","article-title":"244P The Incidence of Infusion Related Reactions with Trastuzumab-Emtansine","volume":"33","author":"Begum","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-\u03b1-1, 3-Galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-008-0831-6","article-title":"Successful Re-Challenge with Panitumumab in Patients Who Developed Hypersensitivity Reactions to Cetuximab: Report of Three Cases and Review of Literature","volume":"63","author":"Saif","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2007.11.7812","article-title":"High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association with Atopic History","volume":"25","author":"Allen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100553","DOI":"10.1016\/j.waojou.2021.100553","article-title":"Nationwide Pharmacovigilance Data for Cetuximab-Induced Anaphylaxis and Predictive Model Validation Using Prospective Specific IgE Detection","volume":"14","author":"Park","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2500\/aap.2019.40.4248","article-title":"Skin Testing in Allergy","volume":"40","author":"Patel","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaip.2015.07.003","article-title":"Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions","volume":"3","author":"Lax","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2003.05.539","article-title":"Expanded Experience with an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/all.12620","article-title":"Delving into Cornerstones of Hypersensitivity to Antineoplastic and Biological Agents: Value of Diagnostic Tools Prior to Desensitization","volume":"70","year":"2015","journal-title":"Allergy"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","article-title":"A Protocol for Risk Stratification of Patients with Carboplatin-Induced Hypersensitivity Reactions","volume":"129","author":"Patil","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"199-e1","DOI":"10.1016\/j.ajog.2007.04.044","article-title":"Use of Cisplatin without Desensitization after Carboplatin Hypersensitivity Reaction in Epithelial Ovarian and Primary Peritoneal Cancer","volume":"197","author":"Callahan","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","article-title":"Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy","volume":"84","author":"Dizon","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"ENDA Drug Provocation Testing in the Diagnosis of Drug Hypersensitivity Reactions: General Considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Soyer, O., Sahiner, U.M., and Sekerel, B.E. (2017). Pro and Contra: Provocation Tests in Drug Hypersensitivity. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071437"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents","volume":"7","author":"Gehlhaar","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/all.12105","article-title":"Hypersensitivity and Desensitization to Antineoplastic Agents: Outcomes of 189 Procedures with a New Short Protocol and Novel Diagnostic Tools Assessment","volume":"68","author":"Pueyo","year":"2013","journal-title":"Allergy"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Con Sensus on Drug Allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1067\/mai.2001.119028","article-title":"Emergency Department Anaphylaxis: A Review of 142 Patients in a Single Year","volume":"108","author":"Brown","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_131","first-page":"72","article-title":"Rapid Drug Desensitization for Hypersensitivity Reactions to Chemotherapy and Monoclonal Antibodies in the 21st Century","volume":"24","author":"Guitart","year":"2014","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jat.3904","article-title":"Application of Spectro-DPRA, KeratinoSensTM and H-CLAT to Estimation of the Skin Sensitization Potential of Cosmetics Ingredients","volume":"40","author":"Cho","year":"2020","journal-title":"J. Appl. Toxicol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.tiv.2011.05.030","article-title":"Intralaboratory Validation of Four in Vitro Assays for the Prediction of the Skin Sensitizing Potential of Chemicals","volume":"25","author":"Bauch","year":"2011","journal-title":"Toxicol. In Vitro"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.yrtph.2014.12.008","article-title":"Assessing Skin Sensitization Hazard in Mice and Men Using Non-Animal Test Methods","volume":"71","author":"Urbisch","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fphar.2016.00204","article-title":"In Vitro Models to Evaluate Drug-Induced Hypersensitivity: Potential Test Based on Activation of Dendritic Cells","volume":"7","author":"Galbiati","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_136","unstructured":"(2022, October 14). OECD The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins 2014. Available online: https:\/\/www.oecd.org\/env\/the-adverse-outcome-pathway-for-skin-sensitisation-initiated-by-covalent-binding-to-proteins-9789264221444-en.htm."},{"key":"ref_137","unstructured":"(2022, October 14). OECD Test No. 442D: In Vitro Skin Sensitisation 2022. Available online: https:\/\/www.oecd.org\/env\/ehs\/testing\/test-no-442d-in-vitro-skin-sensitisation-9789264229822-en.htm."},{"key":"ref_138","unstructured":"(2022, October 14). OECD Test No. 442C: In Chemico Skin Sensitisation 2022. Available online: https:\/\/www.oecd.org\/env\/ehs\/testing\/Test%20No.442C-English.pdf."},{"key":"ref_139","unstructured":"(2022, October 14). OECD Test No. 442E: In Vitro Skin Sensitisation 2022. Available online: https:\/\/www.oecd.org\/env\/test-no-442e-in-vitro-skin-sensitisation-9789264264359-en.htm."},{"key":"ref_140","unstructured":"United Nations (2015). Secretariat Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations. Copyright Law of the United St."},{"key":"ref_141","first-page":"535","article-title":"Comparison of Basophil Activation Test Results in Blood Preserved in Acid Citrate Dextrose and EDTA","volume":"20","author":"Sousa","year":"2010","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"114281","DOI":"10.1016\/j.addr.2022.114281","article-title":"Immunophenotyping: Analytical Approaches and Role in Preclinical Development of Nanomedicines","volume":"185","author":"Newton","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3389\/fimmu.2019.01767","article-title":"Examining Peripheral and Tumor Cellular Immunome in Patients with Cancer","volume":"10","author":"Holl","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_144","first-page":"170","article-title":"Immunoglobulin E-Mediated Severe Anaphylaxis to Paclitaxel","volume":"20","author":"Garcia","year":"2010","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.anai.2020.04.017","article-title":"Rapid Desensitization to Antineoplastic Drugs in an Outpatient Immunoallergology Clinic: Outcomes and Risk Factors","volume":"125","author":"Caiado","year":"2020","journal-title":"Ann. Allergy. Asthma. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40521-020-00238-y","article-title":"Importance of Diagnostics Prior to Desensitization in New Drug Hypersensitivity: Chemotherapeutics and Biologicals","volume":"7","author":"Lleonart","year":"2020","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/all.12886","article-title":"In Vitro Tests for Drug Hypersensitivity Reactions: An ENDA\/EAACI Drug Allergy Interest Group Position Paper","volume":"71","author":"Mayorga","year":"2016","journal-title":"Allergy"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.clinthera.2016.04.034","article-title":"Clinical Utility of Basophil CD203c as a Biomarker for Predicting the Timing of Hypersensitivity Reaction in Carboplatin Rechallenge: Three Case Reports","volume":"38","author":"Iwamoto","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity Reactions to Chemotherapy: Outcomes and Safety of Rapid Desensitization in 413 Cases","volume":"122","author":"Castells","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaip.2014.04.010","article-title":"Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review","volume":"2","author":"Banerji","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The Lymphocyte Transformation Test in the Diagnosis of Drug Hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jaip.2017.03.015","article-title":"Immediate Hypersensitivity Reaction to Chemotherapeutic Agents","volume":"5","author":"Patil","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15476910590930100","article-title":"Evaluation of a Lymph Node Proliferation Assay for Its Ability to Detect Pharmaceuticals with Potential to Cause Immune-Mediated Drug Reactions","volume":"2","author":"Weaver","year":"2005","journal-title":"J. Immunotoxicol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17460441.2018.1437141","article-title":"Tools to Investigate and Avoid Drug-Hypersensitivity in Drug Development","volume":"13","author":"Corsini","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Ginghin\u0103, O., Hudi\u021b\u0103, A., Zaharia, C., Tsatsakis, A., Mezhuev, Y., Costache, M., and G\u0103l\u0103\u021beanu, B. (2021). Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials, 14.","DOI":"10.3390\/ma14092440"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Hudi\u021b\u0103, A., Radu, I.C., Zaharia, C., Ion, A.C., Ginghin\u0103, O., G\u0103l\u0103\u021beanu, B., M\u0103ru\u021bescu, L., Grama, F., Tsatsakis, A., and Gurevich, L. (2021). Bio-and Hemo-Compatible Silk Fibroin PEGylated Nanocarriers for 5-Fluorouracil Chemotherapy in Colorectal Cancer: In Vitro Studies. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050755"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3886\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:08Z","timestamp":1760121368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":156,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043886"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043886","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}